Search | Clinical Trials Finder

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 56
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 52 more

Conditions: Lung Cancer
Interventions: rubitecan; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Dublin, California

Conditions: Lung Cancer
Interventions: oblimersen sodium, docetaxel; Biological · Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 35
States / cities: Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 30 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: trastuzumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment; Combination Product · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 454
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Interventions: panitumumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Los Angeles, California • Philadelphia, Pennsylvania

Conditions: Lung Cancer
Interventions: erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer - Non Small Cell
Interventions: Ipilimumab, Pemetrexed; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Greenbrae, California • Galesburg, Illinois • Quincy, Illinois + 4 more

Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: paclitaxel, carboplatin, bevacizumab, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 842 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Ruxolitinib, Placebo, Pemetrexed, Cisplatin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Fresno, California + 27 more

Conditions: Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: indocyanine green, lidocaine, vinorelbine ditartrate, high performance liquid chromatography, intracellular fluorescence polarization analysis, liquid chromatography, mass spectrometry, pharmacological study; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Recurrent Small Cell Lung Carcinoma
Interventions: Durvalumab, Hypofractionated Radiation Therapy, Stereotactic Body Radiation Therapy, Tremelimumab; Biological · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: suramin, carboplatin, paclitaxel, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Auranofin, Sirolimus, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: Scottsdale, Arizona • Jacksonville, Florida

Conditions: Breast Neoplasms, Pancreatic Neoplasms
Interventions: nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more

Conditions: Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Lung Cancer
Interventions: paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions: LYL797; Biological
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more

Conditions: Lung Neoplasms, Second Primary Lung Cancer (SPLC), Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA, Lung Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: Not listed
Enrollment: 1,826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 65 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more

Conditions: Carcinoma, Non-small Cell Lung
Interventions: REOLYSIN®, Carboplatin, Paclitaxel; Biological · Drug
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Columbus, Ohio

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4052031; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 21
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 14 more

Search by objective public record fields.

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer

A Study to Investigate LYL797 in Adults With Solid Tumors

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors